Zeitschrift für Rheumatologie

, 68:766

Empfehlungen zur Therapie mit Interleukin-1β-blockierenden Wirkstoffen

  • B. Manger
  • M. Gaubitz
  • H. Michels
  • Kommission Pharmakotherapie der DGRh
Qualitätssicherung

Zusammenfassung

Als Interleukin- (IL-)1β blockierender Wirkstoff steht in Deutschland bislang Anakinra (ANR) zur Verfügung (Stand: August 2009), das Erwachsenen in einer Dosierung von 100 mg/Tag, Kindern mit 1–2 mg/kg Körpergewicht/Tag (Tagesmaximaldosis 100 mg) subkutan verabreicht wird. Nach den vorliegenden, durch die Datenlage gestützten Erfahrungen empfiehlt die Deutsche Gesellschaft für Rheumatologie folgende Indikationen für ANR: 1. Rheumatoide Arthritis nach Versagen zweier über mindestens 6 Monate verabreichter konventioneller Basistherapeutika (DMARDs), eines davon Methotrexat (MTX). 2. Adulter Morbus Still sowie systemische juvenile idiopathische Arthritis („juveniler Morbus Still“) bei unzureichendem Ansprechen auf Glukokortikoide bzw. inadäquatem Dauerbedarf sowie Versagen eines konventionellen DMARD, in der Regel MTX. Bei beiden Indikationen muss die Mitbetreuung und Verlaufsdokumentation durch einen internistischen Rheumatologen bzw. Kinderrheumatologen gewährleistet sein. Als weitere Option für eine Behandlung mit ANR werden aufgrund der Datenlage die Cryopyrin-assoziierten periodischen Syndrome (CAPS) empfohlen.

Abgeschlossene Phase-III-Studien mit Wirkungsnachweis für CAPS liegen für das Fusionsprotein Rilonacept (RIL) sowie für den monoklonalen IL-1β-Antikörper Canakinumab vor. In den USA ist RIL unter dem „Orphan Drug Status“ für die Behandlung von CAPS zugelassen.

Schlüsselwörter

Interleukin-1β-Blockade Anakinra Rilonacept Canakinumab Adultes Still-Syndrom Systemische juvenile idiopathische Arthritis Hereditäre periodische Fiebersyndrome 

Recommendations on therapy using interleukin-1β-blocking agents

Abstract

In Germany, the only available interleukin-1β (IL-1β) blocking agent is anakinra (ANR) (as of August 2009) which is given subcutaneously at a dosage of 100 mg/day (adults) and 1–2 mg/kg body weight/day (maximum 100 mg/day) (children), respectively. Based on published data and clinical experience the German Society of Rheumatology (Deutsche Gesellschaft für Rheumatologie) recommends the following indications for ANR: (1) Rheumatoid arthritis, if treatment with two DMARDs (one of the two being methotrexate, MTX) for at least 6 months has failed. (2) Adult-onset and juvenile-onset Still’s disease (systemic juvenile idiopathic arthritis) in the case of insufficient response to glucocorticoids or inadequate long-term dosage, as well as failure of a conventional DMARD, usually MTX. For both indications the treatment should be supervised and documented by a rheumatologist or paediatric rheumatologist. Cryopyrin-associated periodic syndromes (CAPS) are recommended as an additional treatment option for IL-1 blocking therapy.

The efficacy of the fusion protein rilonacept (RIC) and the monoclonal antibody canakinumab in the treatment of CAPS has been proven by randomized, placebo-controlled trials. In the US, RIL was recently approved by the FDA for the treatment of CAPS under the “Orphan Drug Status”.

Keywords

Interleukin-1β blockade Anakinra Rilonacept Canakinumab Adult-onset Still’s disease Systemic juvenile idiopathic arthritis Hereditary periodic fever syndromes 

Literatur

  1. 1.
    Manger B (2002) Empfehlungen der Deutschen Gesellschaft für Rheumatologie zur Therapie der rheumatoiden Arthritis mit dem IL-1-Rezeptorantagonisten Anakinra (Kineret®). Z Rheumatol 61(6):698–700CrossRefPubMedGoogle Scholar
  2. 2.
    Bresnihan B (2001) The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 30(5 Suppl 2):17–20CrossRefPubMedGoogle Scholar
  3. 3.
    Bresnihan B, Alvaro-Gracia JM, Cobby M et al (1998) Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 41(12):2196–2204CrossRefPubMedGoogle Scholar
  4. 4.
    Cohen S, Hurd E, Cush J et al (2002) Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46(3):614–624CrossRefPubMedGoogle Scholar
  5. 5.
    Bresnihan B, Newmark R, Robbins S, Genant HK (2004) Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial. J Rheumatol 31(6):1103–1111PubMedGoogle Scholar
  6. 6.
    Jiang Y, Genant HK, Watt I et al (2000) A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 43(5):1001–1009CrossRefPubMedGoogle Scholar
  7. 7.
    Furst DE, Keystone EC, Kirkham B et al (2008) Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 67 (Suppl 3):iii2–iii25CrossRefPubMedGoogle Scholar
  8. 8.
    Mertens M, Singh JA (2009) Anakinra for rheumatoid arthritis: A systematic review. J Rheumatol 36(6):1118–1125CrossRefPubMedGoogle Scholar
  9. 9.
    Fitzgerald AA, Leclercq SA, Yan A et al (2005) Rapid responses to anakinra in patients with refractory adult-onset Still’s disease. Arthritis Rheum 52(6):1794–1803CrossRefPubMedGoogle Scholar
  10. 10.
    Vasques Godinho FM, Parreira Santos MJ, Canas da SJ (2005) Refractory adult onset Still’s disease successfully treated with anakinra. Ann Rheum Dis 64(4):647–648CrossRefGoogle Scholar
  11. 11.
    Lequerre T, Quartier P, Rosellini D et al (2008) Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 67(3):302–308CrossRefPubMedGoogle Scholar
  12. 12.
    Manger B (2008) Der adulte Morbus Still. Z Rheumatol 67(5):415–422PubMedGoogle Scholar
  13. 13.
    Guignard S, Dien G, Dougados M (2007) Severe systemic inflammatory response syndrome in a patient with adult onset Still’s disease treated with the anti-IL1 drug anakinra: a case report. Clin Exp Rheumatol 25(5):758–759PubMedGoogle Scholar
  14. 14.
    Ruiz PJ, Masliah E, Doherty TA et al (2007) Cardiac death in a patient with adult-onset Still’s disease treated with the interleukin 1 receptor inhibitor anakinra. Ann Rheum Dis 66(3):422–423CrossRefPubMedGoogle Scholar
  15. 15.
    Efthimiou P, Paik PK, Bielory L (2006) Diagnosis and management of adult onset Still’s disease. Ann Rheum Dis 65(5):564–572CrossRefPubMedGoogle Scholar
  16. 16.
    Quartier P, Allantaz F, Cimaz R et al (2008) Efficacy, safety and effect on gene expression profiling of anakinra in systemic-onset juvenile idiopathic arthritis: final results of a randomised, placebo-controlled trial (ANAJIS). Pediatr Rheumatol 6 (Suppl I):P27CrossRefGoogle Scholar
  17. 17.
    Gattorno M, Piccini A, Lasiglie D et al (2008) The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 58(5):1505–1515CrossRefPubMedGoogle Scholar
  18. 18.
    Ohlsson V, Baildam E, Foster H et al (2008) Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA). Rheumatology (Oxford) 47(4):555–556Google Scholar
  19. 19.
    Pascual V, Allantaz F, Arce E et al (2005) Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 201(9):1479–1486CrossRefPubMedGoogle Scholar
  20. 20.
    Guellac N, Niehues T (2008) Interdisziplinäre S2-Leitlinie der juvenilen idiopathischen Arthritis. Klin Pädiatr 220(6):392–402CrossRefPubMedGoogle Scholar
  21. 21.
    Horneff G (2009) Die medikamentöse Therapie der juvenilen idiopathischen Arthritis bei Kindern. Arthritis Rheum 29(2):81–93Google Scholar
  22. 22.
    Aksentijevich I, Masters SL, Ferguson PJ et al (2009) An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 360(23):2426–2437CrossRefPubMedGoogle Scholar
  23. 23.
    Prieur AM, Griscelli C, Lampert F et al (1987) A chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome. A specific entity analysed in 30 patients. Scand J Rheumatol Suppl 66:57–68CrossRefPubMedGoogle Scholar
  24. 24.
    Brydges S, Kastner DL (2006) The systemic autoinflammatory diseases: inborn errors of the innate immune system. Curr Top Microbiol Immunol 305:127–160CrossRefPubMedGoogle Scholar
  25. 25.
    Stojanov S, Kastner DL (2005) Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol 17(5):586–599CrossRefPubMedGoogle Scholar
  26. 26.
    Ben-Chetrit E, Levy M (1998) Colchicine: 1998 update. Semin Arthritis Rheum 28(1):48–59CrossRefPubMedGoogle Scholar
  27. 27.
    Goldfinger SE (1972) Colchicine for familial Mediterranean fever. N Engl J Med 287(25):1302PubMedGoogle Scholar
  28. 28.
    Hawkins PN, Lachmann HJ, Aganna E, McDermott MF (2004) Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 50(2):607–612CrossRefPubMedGoogle Scholar
  29. 29.
    Dybowski F, Jakobs B, Altmeyer P, Braun J (2006) Erfolgreiche Behandlung der klinischen Manifestationen des Muckle-Wells-Syndroms mit Anakinra. Dtsch Med Wochenschr 131(34–35):1863–1866Google Scholar
  30. 30.
    Goldbach-Mansky R, Dailey NJ, Canna SW et al (2006) Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 355(6):581–592CrossRefPubMedGoogle Scholar
  31. 31.
    Lovell DJ, Bowyer SL, Solinger AM (2005) Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum 52(4):1283–1286CrossRefPubMedGoogle Scholar
  32. 32.
    Mirault T, Launay D, Cuisset L et al (2006) Recovery from deafness in a patient with Muckle-Wells syndrome treated with anakinra. Arthritis Rheum 54(5):1697–1700CrossRefPubMedGoogle Scholar
  33. 33.
    O’Connell SM, O’Regan GM, Bolger T et al (2007) Response to IL-1-receptor antagonist in a child with familial cold autoinflammatory syndrome. Pediatr Dermatol 24(1):85–89Google Scholar
  34. 34.
    Rynne M, Maclean C, Bybee A et al (2006) Hearing improvement in a patient with variant Muckle-Wells syndrome in response to interleukin 1 receptor antagonism. Ann Rheum Dis 65(4):533–534CrossRefPubMedGoogle Scholar
  35. 35.
    Yamazaki T, Masumoto J, Agematsu K et al (2008) Anakinra improves sensory deafness in a Japanese patient with Muckle-Wells syndrome, possibly by inhibiting the cryopyrin inflammasome. Arthritis Rheum 58(3):864–868CrossRefPubMedGoogle Scholar
  36. 36.
    Leslie KS, Lachmann HJ, Bruning E et al (2006) Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol 142(12):1591–1597CrossRefPubMedGoogle Scholar
  37. 37.
    Belkhir R, Moulonguet-Doleris L, Hachulla E et al (2007) Treatment of familial Mediterranean fever with anakinra. Ann Intern Med 146(11):825–826PubMedGoogle Scholar
  38. 38.
    Cailliez M, Garaix F, Rousset-Rouviere C et al (2006) Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis. J Inherit Metab Dis 29(6):763CrossRefPubMedGoogle Scholar
  39. 39.
    Calligaris L, Marchetti F, Tommasini A, Ventura A (2008) The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur J Pediatr 167(6):695–696CrossRefPubMedGoogle Scholar
  40. 40.
    Gattorno M, Pelagatti MA, Meini A et al (2008) Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 58(5):1516–1520CrossRefPubMedGoogle Scholar
  41. 41.
    Gattringer R, Lagler H, Gattringer KB et al (2007) Anakinra in two adolescent female patients suffering from colchicine-resistant familial Mediterranean fever: effective but risky. Eur J Clin Invest 37(11):912–914CrossRefPubMedGoogle Scholar
  42. 42.
    Kuijk LM, Govers AM, Frenkel J, Hofhuis WJ (2007) Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra. Ann Rheum Dis 66(11):1545–1546CrossRefPubMedGoogle Scholar
  43. 43.
    Rigante D, Ansuini V, Bertoni B et al (2006) Treatment with anakinra in the hyperimmunoglobulinemia D/periodic fever syndrome. Rheumatol Int 27(1):97–100CrossRefPubMedGoogle Scholar
  44. 44.
    Gerard S, le GB, Maugars Y et al (2007) Lasting remission of a Muckle-Wells syndrome with CIAS-1 mutation using half-dose anakinra. Joint Bone Spine 74(6):659CrossRefPubMedGoogle Scholar
  45. 45.
    Haibel H, Rudwaleit M, Listing J, Sieper J (2005) Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 64(2):296–298CrossRefPubMedGoogle Scholar
  46. 46.
    Tan AL, Marzo-Ortega H, O’Connor P et al (2004) Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis 63(9):1041–1045CrossRefPubMedGoogle Scholar
  47. 47.
    Gibbs A, Gogarty M, Bresnihan B et al (2006) Moderate clinical response and absence of MRI or immunohistological change suggest that Anakinra is ineffective in psoriatic arthritis. Arthritis Rheum 54 (Suppl):S719Google Scholar
  48. 48.
    Jung N, Hoheisel R, Haase I et al (2005) Anakinra (IL-1RA) in the treatment of patients with active psoriatic arthritis refractory to or intolerant of methotrexate (MTX). Ann Rheum Dis 64 (Suppl III):1092Google Scholar
  49. 49.
    Ilowite N, Porras O, Reiff A et al (2009) Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 28(2):129–137CrossRefPubMedGoogle Scholar
  50. 50.
    Goldbach-Mansky R, Shroff SD, Wilson M et al (2008) A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 58(8):2432–2442CrossRefPubMedGoogle Scholar
  51. 51.
    Hoffman HM, Throne ML, Amar NJ et al (2008) Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 58(8):2443–2452CrossRefPubMedGoogle Scholar
  52. 52.
    Alten R, Gram H, Joosten LA et al (2008) The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther 10(3):R67CrossRefPubMedGoogle Scholar
  53. 53.
    Hoffman HM, Wolfe F, Belomestnov P, Mellis SJ (2008) Cryopyrin-associated periodic syndromes: development of a patient-reported outcomes instrument to assess the pattern and severity of clinical disease activity. Curr Med Res Opin 24(9):2531–2543CrossRefPubMedGoogle Scholar
  54. 54.
    Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB et al (2009) Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 360(23):2416–2425CrossRefPubMedGoogle Scholar
  55. 55.
    Ruperto N, Quartier P, Wulffraat N et al (2008) A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA). Pediatr Rheumatol 6 (Suppl 1):S1–S2CrossRefGoogle Scholar
  56. 56.
    McGonagle D, Tan AL, Madden J et al (2008) Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum 58(2):631–633CrossRefPubMedGoogle Scholar
  57. 57.
    So A, De ST, Revaz S, Tschopp J (2007) A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 9(2):R28CrossRefPubMedGoogle Scholar
  58. 58.
    McGonagle D, Tan AL, Shankaranarayana S et al (2007) Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann Rheum Dis 66(12):1683–1684CrossRefPubMedGoogle Scholar
  59. 59.
    Botsios C, Sfriso P, Furlan A et al (2008) Resistant Behcet disease responsive to anakinra. Ann Intern Med 149(4):284–286PubMedGoogle Scholar
  60. 60.
    Vounotrypidis P, Sakellariou GT, Zisopoulos D, Berberidis C (2006) Refractory relapsing polychondritis: rapid and sustained response in the treatment with an IL-1 receptor antagonist (anakinra). Rheumatology (Oxford) 45(4):491–492Google Scholar
  61. 61.
    Wendling D, Govindaraju S, Prati C et al (2008) Efficacy of anakinra in a patient with refractory relapsing polychondritis. Joint Bone Spine 75(5):622–624CrossRefPubMedGoogle Scholar
  62. 62.
    de Koning HD, Bodar EJ, van der Meer JW, Simon A (2007) Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum 37(3):137–148CrossRefGoogle Scholar
  63. 63.
    Schneider SW, Gaubitz M, Luger TA, Bonsmann G (2007) Prompt response of refractory Schnitzler syndrome to treatment with anakinra. J Am Acad Dermatol 56(5 Suppl):S120–S122CrossRefPubMedGoogle Scholar
  64. 64.
    Thonhofer R, Uitz E, Graninger W (2007) Schnitzler’s syndrome–exacerbation after anti-TNF treatment. Rheumatology (Oxford) 46(6):1041–1042Google Scholar
  65. 65.
    Eiling E, Moller M, Kreiselmaier I et al (2007) Schnitzler syndrome: treatment failure to rituximab but response to anakinra. J Am Acad Dermatol 57(2):361–364CrossRefPubMedGoogle Scholar
  66. 66.
    Dybowski F, Sepp N, Bergerhausen HJ, Braun J (2008) Successful use of anakinra to treat refractory Schnitzler’s syndrome. Clin Exp Rheumatol 26(2):354–357PubMedGoogle Scholar
  67. 67.
    Moosig F, Zeuner R, Renk C, Schroder JO (2004) IL-1RA in refractory systemic lupus erythematosus. Lupus 13(8):605–606CrossRefPubMedGoogle Scholar
  68. 68.
    Ostendorf B, Iking-Konert C, Kurz K et al (2005) Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis 64(4):630–633CrossRefPubMedGoogle Scholar
  69. 69.
    Behrens EM, Kreiger PA, Cherian S, Cron RQ (2006) Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis with secondary hemophagocytic lymphohistiocytosis. J Rheumatol 33(10):2081–2084PubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag 2009

Authors and Affiliations

  • B. Manger
    • 1
  • M. Gaubitz
    • 2
  • H. Michels
    • 3
  • Kommission Pharmakotherapie der DGRh
  1. 1.Medizinische Klinik III mit PoliklinikFA Universität Erlangen-NürnbergErlangenDeutschland
  2. 2.Akademie für Manuelle Therapie MünsterDeutschland
  3. 3.Deutsches Zentrum für Kinder- und JugendrheumatologieGarmisch-PartenkirchenDeutschland

Personalised recommendations